Baricitinib - Generic Drug Details

What are the generic sources for baricitinib and what is the scope of patent protection?

Baricitinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baricitinib has fifty-six patent family members in forty-four countries.

One supplier is listed for this compound.

Summary for baricitinib

International Patents:	56
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	101
Patent Applications:	2,603
What excipients (inactive ingredients) are in baricitinib?	baricitinib excipients list
DailyMed Link:	baricitinib at DailyMed

Recent Clinical Trials for baricitinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Phase 4
McGill University Health Centre/Research Institute of the McGill University Health Centre	N/A
Marie Hudson, MD	N/A

See all baricitinib clinical trials

Pharmacology for baricitinib

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

US Patents and Regulatory Information for baricitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019		RX	Yes	No			Y	Y
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019		RX	Yes	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019		RX	Yes	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018		RX	Yes	Yes			Y	Y

International Patents for baricitinib

Country	Patent Number	Title	Estimated Expiration
Colombia	6290658	DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JACK
Dominican Republic	P2010000270	DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK
New Zealand	587928	AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
South Korea	20100121657	AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
Canada	2718271	DERIVES D'AZETIDINE ET DE CYCLOBUTANE EN TANT QU'INHIBITEURS DE JANUS KINASE (JAK) (AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS)
Norway	2017033
Uruguay	31705	DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK

Supplementary Protection Certificates for baricitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2288610	2017/032	Ireland		PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610	132017000078559	Italy		PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215
2288610	1790035-8	Sweden		PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
2288610	315 50012-2017	Slovakia		PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610	2017C/025	Belgium		PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610	33/2017	Austria		PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215
2288610	LUC00027	Luxembourg		PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215